Nano MRNA pivots to investment business, forms holding company

Nano MRNA will establish "Nano Holdings Co., Ltd." as its holding company by April 1, 2026, shifting its focus to investment activities. This move includes a business alliance with SBI Securities Co., Ltd. and SBI Shinsei Corporate Investment Co., Ltd. The alliance involves the formation of a fund targeting JPY 10 bn for investments in unlisted companies and corporate carve-outs, aiming to support promising biotech ventures.

To fund this expansion, Nano MRNA will issue 370,000 stock acquisition rights, raising an estimated JPY 4,470,250,000, and JPY 2.5 bn in private placement bonds. The proceeds will be allocated primarily to redeem the private placement bonds (JPY 2.5 bn) and to fund capital contributions to the investment fund (JPY 1.97 bn) between November 2025 and October 2027.

The company will also amend its articles of incorporation to reflect the new holding company structure and investment objectives, subject to approval at an extraordinary general meeting of shareholders on December 11, 2025. This strategic shift aims to leverage Nano MRNA's expertise in healthcare to foster growth and enhance shareholder value.